View
#Actinogen Quarterly Update Report & App 4C for 3-mth period 30 Jun 2019. “We progressed various studies which will help inform the future development of#Xanamem, especially in relation to dosing & duration of treatment…” said@billketelbey$ACWhttp://bit.ly/2Zl3CjB
Looking at yesterdays volume someone is thinking positive. I take particular interest in the target occupancy trial as this is being conducted with healthy patients and patients with alzheimers (severity unknown). A comment made by Dr Ketelby in a tweet in July (as above), he mentions dosage and duration of treatment are the indications they are receiving from current trials. Like you Rick looking forward to the next announcement. An exciting period coming up.
Jul 29MoreView #Actinogen Quarterly Update Report & App 4C for...
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $73.98M | |||
| Open | High | Low | Value | Volume |
| 2.4¢ | 2.5¢ | 2.3¢ | $146.4K | 5.980M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 1293461 | 2.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.5¢ | 336163 | 5 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| ACW (ASX) Chart |